+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics



Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics



Journal of Medicinal Chemistry 54(8): 2915-2923



The neurotensin receptor subtype 2 (NTS2) is involved in the modulation of tonic pain sensitivity and psychiatric diseases and is, therefore, regarded as a highly attractive pharmacological target protein. Aiming to discover NTS2 selective ligands, we herein describe the identification of screening hits and the chemical synthesis of structural variants leading to the highly potent and NTS2 selective peptide-peptoid hybrids of type 3. The neurotensin mimetics 3a and 3e-g incorporating an N-(4-hydroxyphenethyl)glycine substructure exhibit single digit nanomolar affinity (K(i) = 4.3-8.8 nM) and 1900-12000 fold selectivity over the neurotensin receptor subtype 1 (NTS1). According to functional experiments, the test compounds 3a and 3e-g displayed an inhibition of constitutive mitogen-activated protein kinase (MAPK) activity exceeding 2.6-4.6 times the inverse agonist activity of the endogenous ligand neurotensin.

(PDF emailed within 0-6 h: $19.90)

Accession: 052644189

Download citation: RISBibTeXText

PMID: 21446649

DOI: 10.1021/jm200006c


Related references

Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. Bioorganic & Medicinal Chemistry Letters 15(12): 3091-3095, 2005

Evidence for additional neurotensin receptor subtypes: Neurotensin analogs that distinguish between neurotensin-mediated hypothermia and antinociception. Brain Research 792(2): 246-252, 1998

Effect of the neurotensin receptor antagonist SR48692 on the expression of neurotensin and neurotensin receptor mRNA in rat brain. Society for Neuroscience Abstracts 19(1-3): 1184, 1993

Microdialysis studies with intrastriatal neurotensin 1-13 and neurotensin 8-13 on striatal GABA and dopamine release in the awake rat evidence for neurotensin receptor heterogeneity in the neostriatum. Society for Neuroscience Abstracts 22(1-3): 76, 1996

Endogenous neurotensin down-regulates dopamine efflux in the nucleus accumbens as revealed by SR-142948A, a selective neurotensin receptor antagonist. Journal of Neurochemistry 77(6): 1542-1552, June, 2001

Novel potent neurotensin mimetics. Abstracts of Papers American Chemical Society 215(1-2): MEDI 148, 1998

Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. Oncotarget 5(18): 8235-8251, 2015

Identification of N-[(5-{[(4-methylphenyl)sulfonyl]amino}-3-(trifluoroacetyl)-1H-indol-1-yl)acetyl]-l-leucine (NTRC-824), a neurotensin-like nonpeptide compound selective for the neurotensin receptor type 2. Journal of Medicinal Chemistry 57(17): 7472-7477, 2014

The non-peptide neurotensin receptor antagonist SR48692 is not a potent antagonist of neurotensin(8-13) responses of rat substantia nigra neurones in vitro. Neuroscience Letters 172(1-2): 175-178, 1994

New neurotensin 8-13 mimetics with potent in vivo activity. Abstracts of Papers American Chemical Society 208(1-2): MEDI 8, 1994

Effects of SR 48692 on neurotensin-induced calcium-activated chloride currents in the Xenopus oocyte expression system: Agonist-like activity on the levocabastine-sensitive neurotensin receptor and absence of antagonist effect on the levocabastine insensitive neurotensin receptor. Neuroscience Letters 223(3): 193-196, 1997